Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TEM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTempus AI to acquire Personalis for $16.25/share in stock-and-optional-cash merger
Filed July 20, 2026 · Period ending July 20, 2026 · ~1 min read
Key Changes
-
high
Tempus signed definitive agreement to acquire Personalis through two-step merger; consideration is Tempus Class A stock valued at $16.25/share, with Tempus holding option to pay up to 50% in cash at same price.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Exchange ratio is 0.3356 shares if Tempus trades at or below $48.42, or $16.25 divided by Tempus' 15-day VWAP if above that floor; Personalis may terminate if Tempus falls below $46.00 shortly before closing.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Closing requires Personalis shareholder approval (majority vote), HSR clearance, Nasdaq listing approval for Tempus shares, and SEC registration statement effectiveness; outside date is April 20, 2027 with two potential six-month extensions.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Mutual termination fees of approximately $76.8 million; Personalis pays if it changes board recommendation, Tempus pays if deal fails due to antitrust issues caused by Tempus' breach of obligations.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
Tempus AI announced a definitive agreement to acquire Personalis, a genomic testing company, in a stock-and-optional-cash merger valued at $16.25 per Personalis share. The transaction has been approved by both boards, with Personalis' board recommending shareholder adoption.
Personalis shareholders will receive Tempus Class A Common Stock based on an exchange ratio tied to the $16.25 valuation, with a floor of 0.3356 shares if Tempus trades at or below $48.42. Tempus may elect to pay up to 50% of the consideration in cash at $16.25 per share, with the remainder in stock.
The deal faces standard closing conditions including Personalis shareholder approval by majority vote, HSR antitrust clearance, Nasdaq listing approval for the Tempus shares to be issued, and SEC registration statement effectiveness. The transaction is structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. The outside date is April 20, 2027, with two potential six-month extensions if regulatory approvals are pending. Mutual termination fees of approximately $76.8 million protect both parties under specified circumstances. For Tempus shareholders, the acquisition represents a strategic expansion in genomic testing, with execution risk tied to regulatory clearance and Personalis shareholder approval.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 20, 2026, Tempus AI, Inc., a Nevada corporation (“Tempus”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Tempus, Personalis, Inc., a Delaware corporation (“Personalis”), Aviary Development, Inc., a Delaware corporation and a wholly-owned subsidiary of Tempus (“Merger Sub I”) and Toucan Development, LLC, a Nevada limited liability company and a wholly-owned subsidiary of Tempus (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, (a) Merger Sub I will be merged with and into Personalis (the “First Merger”), with Personalis surviving the First Merger as a wholly-owned subsidiary of Tempus (the “First Surviving Corporation”), and (b) as part of the same overall transaction, immediately after the First Merger, the First Surviving Corporation will merge with and into Merger Sub II (the “Second Merger” and, together with the First Merger, the “Mergers”), with Merger Sub II surviving as a wholly-owned subsidiary of Tempus (the “Surviving Company”).
Tempus AI signed a definitive merger agreement to acquire Personalis through a two-step merger structure. Personalis will become a wholly-owned subsidiary of Tempus upon closing. The transaction has been approved by both boards, with Personalis' board recommending shareholder adoption.
Added in current filing · verify on EDGAR →
a number of validly issued, fully paid and nonassessable shares of Tempus Class A Common Stock equal to the Exchange Ratio (the “Stock Consideration”); provided, however, that Tempus may elect (a “Tempus Cash Election”) to pay cash for up to 50% of the aggregate number of outstanding shares of Personalis Common Stock (which such amount may be automatically reduced to preserve the intended tax treatment of the Mergers). If Tempus makes a Tempus Cash Election, each holder will receive: (a) an amount in cash equal to the Per Share Cash Consideration of $16.25 per share, without interest (the “Cash Consideration”), for such holder’s pro rata portion of the Eligible Shares subject to the Tempus Cash Election (determined by multiplying the holder’s Eligible Shares by a fraction equal to the Cash Share Number divided by the total shares of Personalis Common Stock issued and outstanding immediately prior to the Effective Time (other than Cancelled Shares)), and (b) the Stock Consideration for the holder’s remaining Eligible Shares
Personalis shareholders will receive Tempus Class A Common Stock based on an exchange ratio tied to $16.25 per share. Tempus may elect to pay up to 50% of the consideration in cash at $16.25 per share, with the remainder in stock. The exchange ratio is 0.3356 if Tempus stock trades at or below $48.42, or $16.25 divided by Tempus' volume-weighted average price over fifteen trading days prior to closing if above that floor.
Added in current filing · verify on EDGAR →
Under the terms of the Merger Agreement, the completion of the Mergers is subject to certain customary closing conditions, including, among others: (i) the approval of the Mergers and adoption of the Merger Agreement by the affirmative vote of the holders of a majority of the outstanding shares of Personalis Common Stock entitled to vote thereon; (ii) the approval for listing on Nasdaq of the Tempus Class A Common Stock to be issued in the Mergers; (iii) the effectiveness of a registration statement on Form S-4 filed by Tempus registering the Tempus Class A Common Stock to be issued in connection with the Mergers; (iv) the accuracy of the parties’ respective representations and warranties in the Merger Agreement, subject to specified materiality qualifications; (v) compliance by the parties with their respective covenants in the Merger Agreement in all material respects; (vi) the absence of any law or order restraining, enjoining or otherwise prohibiting the consummation of the Mergers; (vii) the expiration or termination of the required waiting period applicable to the Mergers under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the approval or issuance of any other filing or consent or the expiration or termination of any other waiting period applicable to the Mergers, in accordance with the Merger Agreement; (viii) the receipt by Personalis of an opinion to the effect that the Mergers will qualify as a reorganization for U.S. federal income tax purposes; and (ix) the absence of a Personalis Material Adverse Effect (in the case of Tempus’ obligation to close) or a Tempus Material Adverse Effect (in the case of Personalis’s obligation to close).
Closing requires Personalis shareholder approval by majority vote, Nasdaq listing approval for Tempus shares, SEC registration statement effectiveness, HSR clearance, and customary conditions including no material adverse effects. The transaction is intended to qualify as a tax-free reorganization. Personalis may terminate if Tempus stock falls below $46.00 shortly before closing.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
each In-the-Money Personalis Option (i) held by a former employee or any non-employee director (whether vested or unvested) or (ii) held by any current service provider that is vested and exercisable, in each case, that is outstanding and unexercised immediately prior to the Effective Time will be cancelled and converted into the right to receive the Stock Consideration in respect of each Net Option Share subject to such In-the-Money Personalis Option immediately prior to the Effective Time; ... each other In-the-Money Personalis Option that is outstanding and unexercised immediately prior to the Effective Time will be assumed by Tempus and converted automatically into an option to purchase a number of shares of Tempus Class A Common Stock equal to the product obtained by multiplying (x) the number of shares subject to such In-the-Money Personalis Option immediately prior to the Effective Time, by (y) the Exchange Ratio, with an exercise price per share of Tempus Class A Common Stock equal to (i) the per share exercise price for each share subject to the corresponding Personalis Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio; ... each Out-of-the-Money Personalis Option outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) will be cancelled without any consideration
In-the-money Personalis stock options held by former employees or directors will be cashed out for stock consideration. Other in-the-money options will convert to Tempus options using the exchange ratio. Out-of-the-money options are cancelled with no value. Personalis RSUs and PSUs will generally convert to Tempus equity awards, with director RSUs and a portion of PSUs vesting at closing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 20, 2026 · How we verify